Overview of anti‐BCMA CAR‐T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma
Author:
Affiliation:
1. Department of Molecular and Cellular Pharmacology School of Pharmaceutical Science and Technology Tianjin University Tianjin China
Funder
National Natural Science Foundation of China
Publisher
Wiley
Subject
Immunology,General Medicine
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/sji.12910
Reference110 articles.
1. CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
2. Rapid Transduction and Expansion of Transduced T Cells with Maintenance of Central Memory Populations
3. Multiple myeloma
4. BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy
5. Clinical development of CAR T cells—challenges and opportunities in translating innovative treatment concepts
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. CAR NK92 Cells Targeting BCMA Can Effectively Kill Multiple Myeloma Cells Both In Vitro and In Vivo;Biomedicines;2024-01-22
2. Drug from Marine Sampling to Factory;Marine Ecology: Current and Future Developments;2023-11-02
3. Facial Nerve Palsy After Chimeric Antigen Receptor T-Cell Therapy;Mayo Clinic Proceedings;2023-10
4. CD19-Targeted Chimeric Antigen Receptor T-cell Therapy for Concomitant Diffuse Large B-cell Lymphoma and Multiple Myeloma;Cureus;2023-09-01
5. Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023;Human Vaccines & Immunotherapeutics;2023-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3